Russell Investments Group Ltd. lifted its holdings in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 114.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,644 shares of the biotechnology company’s stock after purchasing an additional 23,305 shares during the quarter. Russell Investments Group Ltd. owned 0.23% of Enanta Pharmaceuticals worth $3,532,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Meadow Creek Investment Management LLC acquired a new stake in shares of Enanta Pharmaceuticals during the first quarter worth about $110,000. SG Americas Securities LLC acquired a new stake in shares of Enanta Pharmaceuticals during the first quarter worth about $112,000. Riverhead Capital Management LLC acquired a new stake in shares of Enanta Pharmaceuticals during the first quarter worth about $129,000. Glen Harbor Capital Management LLC acquired a new stake in shares of Enanta Pharmaceuticals during the first quarter worth about $140,000. Finally, Macquarie Group Ltd. raised its position in shares of Enanta Pharmaceuticals by 350.0% during the fourth quarter. Macquarie Group Ltd. now owns 2,700 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 2,100 shares during the period. 76.21% of the stock is currently owned by institutional investors.
Shares of Enanta Pharmaceuticals opened at $115.90 on Monday, MarketBeat Ratings reports. Enanta Pharmaceuticals Inc has a 52-week low of $33.15 and a 52-week high of $122.43. The company has a market capitalization of $2.23 billion, a P/E ratio of 41.25 and a beta of 1.00.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Tuesday, May 8th. The biotechnology company reported $0.61 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.08. Enanta Pharmaceuticals had a return on equity of 18.50% and a net margin of 31.60%. The business had revenue of $44.00 million for the quarter, compared to analyst estimates of $40.77 million. During the same quarter last year, the firm earned ($0.28) EPS. Enanta Pharmaceuticals’s revenue for the quarter was up 388.9% compared to the same quarter last year. equities analysts expect that Enanta Pharmaceuticals Inc will post 3.36 earnings per share for the current year.
ENTA has been the topic of a number of research analyst reports. ValuEngine raised Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 2nd. Roth Capital initiated coverage on Enanta Pharmaceuticals in a research report on Wednesday, June 6th. They set a “buy” rating and a $133.00 price target on the stock. Oppenheimer initiated coverage on Enanta Pharmaceuticals in a research report on Thursday, May 24th. They set a “buy” rating and a $135.00 price target on the stock. BidaskClub raised Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, March 14th. Finally, Zacks Investment Research lowered Enanta Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 10th. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and two have given a strong buy rating to the stock. Enanta Pharmaceuticals has a consensus rating of “Buy” and an average price target of $83.71.
In other Enanta Pharmaceuticals news, Treasurer Paul J. Mellett sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 11th. The stock was sold at an average price of $120.57, for a total value of $1,808,550.00. Following the completion of the transaction, the treasurer now directly owns 88,158 shares in the company, valued at $10,629,210.06. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Nathalie Adda sold 4,225 shares of the firm’s stock in a transaction that occurred on Monday, April 16th. The shares were sold at an average price of $85.58, for a total value of $361,575.50. Following the completion of the transaction, the vice president now owns 10,225 shares of the company’s stock, valued at $875,055.50. The disclosure for this sale can be found here. In the last three months, insiders sold 52,535 shares of company stock worth $5,730,391. 10.56% of the stock is owned by insiders.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.